Explore Evolut™ durability

You’ve chosen TAVR, now choose durability.

Alert Indications, Safety, and Warnings

Your patients rely on you as their trusted cardiologist over their lifetime.

Give them a proven treatment option to treat symptomatic severe aortic stenosis. When you believe TAVR is the best treatment for your patients, you may not be thinking of a particular valve. Maybe you should be.

Middle-aged couple sitting at a table across from a healthcare professional holding a model of an anatomical heart

Explore the durability difference.

CoreValve™/Evolut TAVR is the first and only platform to outperform surgery in valve durability at five years.1

Expand All

Structural valve deterioration (SVD) cumulative incidence at five years

CoreValve/Evolut platform pooled analysis1

5-year SVD adjusted for competing risk of mortality

Blue and gray line chart comparing the five-year structural valve dysfunction data of Medtronic CoreValve/Evolut to surgery

The first and only TAVR platform to demonstrate significantly lower SVD than SAVR.

SVD was defined as ≥ moderate hemodynamic valve deterioration (HVD): Increase in mean gradient ≥ 10 mmHg from discharge/30-day echo to last available echo AND mean gradient ≥ 20 mmHg at last available echo OR new onset/increase of intraprosthetic aortic regurgitation (AR) ≥ moderate.

A decade of durability

4-year excellent hemodynamics from the low risk trial

Back to top

Durability starts with design.

Built on the original CoreValve platform, Evolut TAVR is engineered with specific design elements to promote sustained valve performance with consistently large EOAs and low gradients over time. It also provides the ability to access the coronary arteries.

  1. Supra annular positioning
  2. Nitinol frame
  3. External tissue wrap
  4. Higher outward canted commissures
Discover more data
Evolut PRO transcatheter aortic valve (TAV) with callouts highlighting four features

Back to top

Performance that matters

Sustained valve performance helps keep your patients alive and out of the hospital.

Decreased gradients and large EOAs can:

Reduce mortality5,6

Avoid heart failure6,7

Extend valve longevity8

Help keep patients alive1

Explore more

Back to top

When TAVR is an option for your patients with symptomatic severe aortic stenosis, choose the durability difference for your long-term patient management needs. 

Think Evolut First
Female healthcare professional wearing blue scrubs speaking to female patient who is blurred in the foreground

Back to top

Connect with us on social.

LinkedIn: Medtronic Cardiac and Vascular
YouTube: Medtronic Cardiac YouTube

Stay informed.

Sign up to get the latest information and resources from Medtronic on treating aortic stenosis and the Evolut platform.

Sign up now

References

1

O'Hair D, Yakubov SJ, Grubb KJ, et al. Structural Valve Deterioration After Self-Expanding Transcatheter or Surgical Aortic Valve Implantation in Patients at Intermediate or High Risk. JAMA Cardiol. February 1, 2023;8(2):111–119.

2

Jørgensen T. Ten-year follow-up after transcatheter or surgical aortic valve implantation in severe aortic valve stenosis. Presented at ESC Congress; August 2023.

3

Reardon M, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Aortic Stenosis Patients at Low Surgical Risk: 4-Year Outcomes from the Evolut Low Risk Trial. Presented at TCT; October 2023.

4

Forrest JK, Deeb GM, Yakubov SJ, et al. 4-Year Outcomes of Patients With Aortic Stenosis in the Evolut Low Risk Trial. J Am Coll Cardiol. November 28, 2023;82(22):2163–2165.

5

Playford D, Stewart S, Celermajer D, et al. Poor survival with impaired valvular hemodynamics after aortic valve replacement: the national echo database Australia study. J Am Soc Echo. September 2020;33(9)1077–1086.

6

Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-patient mismatch in patients undergoing transcatheter aortic valve replacement: from the STS/ACC TVT Registry. J Am Coll Cardiol. December 4, 2018;72(22):2701–2711. 

7

Anand V, Ali MA, Naser J, et al. Incidence, mechanisms, and predictors of mean systolic gradients ≥20 mm Hg after transcatheter aortic valve implantation. Am J Cardiol. March 15, 2020;125(6):941–947.

8

O’Hair D. Relationship of Hemodynamic Valve Deterioration (HVD) and Late Clinical Outcomes after TAVR with a Self-Expanding Bioprosthesis and Surgery. Presented at American College of Cardiology 70th Annual Scientific Session & Expo; May 2021.